Blacksburg, VA – April 20, 2018 – Landos Biopharma Chairman and CEO Dr. Josep Bassaganya-Riera has been awarded the 2018 Research Excellence Award from the Biocomplexity Institute of Virginia Tech. The awards ceremony was held at Steger Hall.

Josep is a captain of industry, innovator, serial entrepreneur, and thought leader in biotech. He has published over 150 peer-reviewed publications, holds numerous patents, has founded 3 award-winning Companies (Landos BiopharmaBioTherapeutics and Pervida), raising over $65 million in non-dilutive and equity financing rounds, and was recently named 2017 Innovator of the Year by the Roanoke-Blacksburg Technology Council. In 2018, Pervida was named Technology Company of the year by the Chamber of Commerce.

“It is a distinct honor and a privilege to accept the prestigious 2018 Biocomplexity Institute Research Excellence Award,” said Dr. Bassaganya-Riera. “We embarked on a beautiful new journey with a bold vision of decoding the complexity of immune responses for accelerating the path to cures. This award illustrates the scientific foundations that underpin and support building several companies that are truly and uniquely transformational in promoting health and treating widespread and debilitating human diseases.”

Dr. Bassaganya-Riera’s work at Virginia Tech’s Nutritional Immunology and Molecular Medicine Laboratory (NIMML) has provided a better understanding of the immune system’s response to some of the most common diseases which represent a state of high unmet treatment need. This transformative computational modeling approach has been found to improve efficiency, decrease cost, and reduce the time required to find treatments for debilitating diseases including autoimmune diseases and systemic chronic diseases such as obesity, heart disease, and diabetes. Under his leadership, NIMML received funding from both the National Institutes of Health and the Defense Threat Reduction Agency.

Dr. Bassaganya-Riera founded Landos Biopharma, an emerging biotech company focused on developing new oral treatments for patients with autoimmune diseases, in 2017. Landos recently closed a $10 million Series A round, and it is advancing its robust pipeline of novel oral therapeutics for autoimmune diseases, a $100 billion market, toward clinical testing and commercialization. Landos’ lead candidate, BT-11, is poised to enter clinical trials in 2018 for Crohn’s disease and ulcerative colitis; and Landos is filing two investigational new drug (IND) applications for BT-11 and entering Phase 1 clinical testing this summer based on the successful validation and de-risking of the BT-11 program during several pre-IND meetings with FDA. Phase 2 clinical studies in Crohn’s disease and ulcerative colitis patients with moderate to severe disease are anticipated in early 2019.

About Landos Biopharma, Inc.—Accelerated Paths to Cures

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, oral, locally-acting small molecule targeting the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD) and is expected to enter clinical testing for Crohn’s disease and ulcerative colitis in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA.

For more information, please visit or contact or follow us @Landosbio.

Company Contacts:

Landos Biopharma:

Josep Bassaganya-Riera